VivoSim Labs, Inc. VIVS
0.26 USD -0.03 (-10.53%)
Regular-session close
0.24 -0.02 -6.90%
After hours · Nov 20, 7:59 PM ET
0.2435 Day range 0.3808
0.12 52-week range 3.40
- YTD
- -85.59%
- 1 year
- -87.98%
5D +0.1386 (+113.42%)
- Market cap
- 5.29M
- EPS (ttm)
- -3.41
- YTD return
- -85.59%
- 1-year return
- -87.98%
- Volume
- 149.18M
- Avg volume
- 13.67M
- Open
- 0.28
- Previous close
- 0.2915
- Day's range
- 0.2435 – 0.3808
- 52-week range
- 0.12 – 3.40
Fundamental scorecard
4 of 25 checks passed on VIVS’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
VIVS Revenue — quarterly 51.00K
VIVS Net income — quarterly -475.00K
VIVS EPS — quarterly -0.03
News
VivoSim Labs (VIVS) Stock Jumps 21% After Hours: What’s Driving the Move
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
S&P 500 Gains 1%; US Initial Jobless Claims Edge Higher VivoSim Labs Enters Seven-Figure Agreement With A Top-10 Global Pharmaceutical Company For Its NAMkind Testing Services; Company Expects FY27 Revenue To Exceed Prior Guidance Of 500%+ Growth
VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027
VivoSim Labs to Showcase Breakthrough Multiparametric NAMkind™ Liver and Intestine Data at the 2026 American College of Toxicology (ACT) Annual Meeting VivoSim Labs Q2 EPS $(0.03) Up From $(0.98) YoY, Sales $51.000K Up From $28.000K YoY
VivoSim Labs Partners With Chemveda Life Sciences To Test, Screen AI-Derived Drug Compounds In VivoSim's NAMkind 3D Tissue Models
VivoSim Labs To Extend Its Human Tissue Platform Beyond Toxicology With Efficacy Testing Services Built On NAMkind Disease Models Of The Liver And Intestine
Your note
Sign in to keep a note on VIVS — it syncs with the Stock Master app.
